Project Grant R43AG071142
Award Date
1/15/21
Completion Date
4/30/22
Dollars Obligated
$1M
Federal Agency
National Institute on Aging
Awardee
Nemalife Inc. (JPKVJPK1ZYF2)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
Duke University received a $1,019,484.58 Project Grant award from the National Institutes of Health's National Institute on Aging under the Aging Research program (CFDA 93.866) for the period September 1, 2021 through May 31, 2022. The award will support research using the nematode C. elegans as a model organism to study aging-associated neurodegeneration at the molecular level, with the goals of uncovering novel mechanisms underlying this process and establishing C. elegans neurons as a...
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will support Sxrna Technologies, Inc. in developing an organoid toolkit for Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). The company aims to create a platform for identifying senescent cells in living tissue, which can provide insights into the aging process and enable high-throughput drug screening in complex 3D tissue models. Specifically, the grant will fund...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
The National Institute on Aging (CFDA 93.866) awarded a $1,274,993 Project Grant to Epicypher, Inc. to develop a new approach called Reverse Transcribe & Tagmentation (RT & TAG) for identifying chromatin-associated RNAs (CARNAs), including nascent RNA transcripts, to accelerate aging and Alzheimer's disease/age-related dementia (AD/ADRD) research. The central innovation is an immunotethering-based method for in situ targeted tagmentation of CARNAs. The project also involves developing...
The National Institute on Aging (NIA), under the Federal Aging Research program (CFDA 93.866), awarded a $245,148 project grant to Eyenexo LLC to develop an automated rodent behavior testing system for non-invasively assessing early-stage Alzheimer's disease (AD). The project aims to develop a behavior biomarker that can differentiate AD from normal aging by studying defensive behaviors triggered by looming stimuli, which are linked to early AD pathology in the midbrain region. The 2-year...
This $1,031,595 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The awardee, Dana-Farber Cancer Institute, will define the landscape and mechanisms of protein redox regulation during aging. Specifically, the Institute will systematically map cysteine oxidation networks in mouse tissues to determine their role in coordinating protein complex assemblies relevant to age-related...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $1,055,313 in funding to the University of Miami to conduct research on the role of glial cells in the aging process. Specifically, the researchers will leverage C. elegans genetics and advanced imaging and supplementation methods to investigate how the glial ion channel CLH-1 controls organismal aging. The key objectives are to establish the function of glial CLH-1 in influencing aging and to...
The National Institute on Aging (NIA) awarded a $514,862 Project Grant (CFDA 93.866 - Aging Research) to Neuroindx, a for-profit, woman-owned small business, to develop an on-chip functional assay for identifying candidate microtubule-binding drugs to treat Alzheimer's Disease and related disorders (ADRDs). The goal of the project is to create an in vitro assay that can replicate key features of the neuronal microtubule microenvironment and use kinesin-based readouts to measure the ability of...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $2,549,590 to Epicypher, Inc. to develop a novel approach called CUTANA-RH for genome-wide profiling of R-loops. R-loops are DNA-RNA hybrid structures implicated in aging and neurodegenerative diseases like Alzheimer's. The first innovation is a modular immunotethering strategy for mapping R-loops that uses a catalytically inactive RNase H1 enzyme instead of an unreliable...